Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-625 (Maralixibat) in Progressive Familial Intrahepatic Cholestasis
NCT05543187Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of maralixibat in progressive familial intrahepatic cholestasis (PFIC) (2 cohorts), sponsored by Takeda. Primary endpoint: Change in Average Morning Itch Reported Outcome (Observer Instrument) Severity at 26 weeks. Started Jan 2023; status: completed.
02
Drugs
maralixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT05543187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543187.